PROFILE FOR ACST.
EARNINGS HISTORY
| +0.26 BEAT | Nov, 11, 2024 Actual: -0.19 Estimated: -0.45 |
| +0.04 BEAT | Aug, 09, 2024 Actual: -0.24 Estimated: -0.28 |
| +0.17 BEAT | Jun, 21, 2024 Actual: -0.18 Estimated: -0.35 |
| +0.09 BEAT | Feb, 12, 2024 Actual: -0.21 Estimated: -0.3 |
| +0.1 BEAT | Nov, 13, 2023 Actual: -0.19 Estimated: -0.29 |
| +0.29 BEAT | Aug, 11, 2023 Actual: -0.34 Estimated: -0.63 |
| +0.24 BEAT | Feb, 14, 2023 Actual: -0.54 Estimated: -0.78 |
| -0.06 MISS | Feb, 14, 2022 Actual: -0.54 Estimated: -0.48 |
NEWS FEED
 | Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. 2024-10-25 08:00:00 Name Change Reflects Extensive Scientific and Corporate Brand Equity Previously Established under Grace Therapeutics Grace Therapeutics will begin trading on Nasdaq under the trading symbol “GRCE” effective October 28, 2024 Virtual Key Opinion Leader Event to be held on November 20 th PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTx-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that it is changing its name to Grace Therapeutics, Inc. (Grace Therapeutics). |  | Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104 2024-09-25 07:30:00 Data Readout Expected Early Calendar 2025; NDA Submission on Track for 1H Calendar 2025 Data Readout Expected Early Calendar 2025; NDA Submission on Track for 1H Calendar 2025 |  | Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024-09-05 10:35:00 PRINCETON, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference, to be held September 9th – 11th in New York, NY. |  | Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update 2024-08-09 08:00:00 PRINCETON, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced financial results and business highlights for the quarter ended June 30, 2024. |  | Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year? 2024-07-10 10:41:26 Here is how Acasti Pharma (ACST) and Cigna (CI) have performed compared to their sector so far this year. |  | Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial 2024-06-27 16:05:00 Company Anticipates Completion of Patient Enrollment in the STRIVE-ON Trial in Late 2024 to Early 2025, with Potential NDA Submission on Track for 1H Calendar 2025 Company Anticipates Completion of Patient Enrollment in the STRIVE-ON Trial in Late 2024 to Early 2025, with Potential NDA Submission on Track for 1H Calendar 2025 |  | Acasti Announces Year-End 2024 Financial Results, Provides Business Update 2024-06-21 08:00:00 PRINCETON, N.J., June 21, 2024 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced financial results and business highlights for the year ended March 31, 2024. |  | Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024 2024-06-18 12:31:50 As the main stock indices like the S&P 500 and Nasdaq continue to climb, penny stocks are becoming attractive for those seeking significant returns. Despite their reputation for extreme price fluctuations and high risk, they offer the potential for impressive gains, especially in a bull market. |  | Acasti Pharma to Attend BIO International Convention 2024 2024-05-28 16:05:00 PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel, injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that the Company will be participating in the BIO International Convention taking place at the San Diego Convention Center from June 3-6, 2024. |  | The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom 2024-05-23 06:45:00 Novavax (NASDAQ: NVAX ) stock was among the laggards in the race for the vaccine against COVID-19. Unsurprisingly, NVAX stock plunged from highs of $320 in 2021 to recent lows of $3.5. |